Literature DB >> 1717070

Activated and unactivated platelet adhesion to monocytes and neutrophils.

H M Rinder1, J L Bonan, C S Rinder, K A Ault, B R Smith.   

Abstract

To examine the possible receptor-ligand pairs mediating adhesion of activated and "unactivated" platelets to leukocytes and the kinetics of leukocyte-platelet binding, we developed a flow cytometric assay using isolated cell fractions to accurately measure heterotypic cell adhesion, including both total leukocyte-platelet conjugate formation as well as the number of platelets bound per leukocyte. We have shown that (1) activated platelet binding to both polymorphonuclear leukocytes (PMN) and monocytes is dependent on both a specific epitope (blocked by monoclonal antibody G1) of granule membrane protein-140 (GMP-140) and the presence of divalent cations; (2) unactivated platelets bind to 87% of viable, resting monocytes but to only 34% of PMN; (3) the receptor(s) on unactivated platelets that mediate adhesion to PMN and monocytes do not require divalent cations and become nonfunctional after thrombin activation; and (4) the kinetics of platelet adhesion to monocytes and PMN indicate that monocyte adhesion is favored over neutrophil adhesion. We conclude that platelet-heterotypic cell adhesion is a dynamic process reflecting the activation status of the platelet and differential binding abilities of leukocytes.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1717070

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  34 in total

1.  Monte Carlo simulation of the heterotypic aggregation kinetics of platelets and neutrophils.

Authors:  I J Laurenzi; S L Diamond
Journal:  Biophys J       Date:  1999-09       Impact factor: 4.033

Review 2.  Current concepts of platelet activation: possibilities for therapeutic modulation of heterotypic vs. homotypic aggregation.

Authors:  Gabriella Passacquale; Albert Ferro
Journal:  Br J Clin Pharmacol       Date:  2011-10       Impact factor: 4.335

Review 3.  [Thrombocytopathy and blood complications in uremia].

Authors:  Walter H Hörl
Journal:  Wien Klin Wochenschr       Date:  2006-04       Impact factor: 1.704

4.  Complete reversal of acid-induced acute lung injury by blocking of platelet-neutrophil aggregation.

Authors:  Alexander Zarbock; Kai Singbartl; Klaus Ley
Journal:  J Clin Invest       Date:  2006-12       Impact factor: 14.808

5.  Blockade of C5a and C5b-9 generation inhibits leukocyte and platelet activation during extracorporeal circulation.

Authors:  C S Rinder; H M Rinder; B R Smith; J C Fitch; M J Smith; J B Tracey; L A Matis; S P Squinto; S A Rollins
Journal:  J Clin Invest       Date:  1995-09       Impact factor: 14.808

Review 6.  Bidirectional modulation of platelet and polymorphonuclear leukocyte activities.

Authors:  A Del Maschio; E Dejana; G Bazzoni
Journal:  Ann Hematol       Date:  1993-07       Impact factor: 3.673

7.  Prasugrel metabolites inhibit neutrophil functions.

Authors:  Elisabetta Liverani; Mario C Rico; Analia E Garcia; Laurie E Kilpatrick; Satya P Kunapuli
Journal:  J Pharmacol Exp Ther       Date:  2012-10-24       Impact factor: 4.030

Review 8.  Role of platelets in neuroinflammation: a wide-angle perspective.

Authors:  Lawrence L Horstman; Wenche Jy; Yeon S Ahn; Robert Zivadinov; Amir H Maghzi; Masoud Etemadifar; J Steven Alexander; Alireza Minagar
Journal:  J Neuroinflammation       Date:  2010-02-03       Impact factor: 8.322

9.  Oxidation of a specific methionine in thrombomodulin by activated neutrophil products blocks cofactor activity. A potential rapid mechanism for modulation of coagulation.

Authors:  C B Glaser; J Morser; J H Clarke; E Blasko; K McLean; I Kuhn; R J Chang; J H Lin; L Vilander; W H Andrews; D R Light
Journal:  J Clin Invest       Date:  1992-12       Impact factor: 14.808

10.  Platelet-dependent accumulation of leukocytes in sinusoids mediates hepatocellular damage in bile duct ligation-induced cholestasis.

Authors:  M W Laschke; S Dold; M D Menger; B Jeppsson; H Thorlacius
Journal:  Br J Pharmacol       Date:  2007-11-19       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.